By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the ...

According to market observers, shares of the company are available at a premium of ₹101 in the grey market today ...

Anthem Biosciences IPO got fully subscribed at 1.15 times on the second day of share sale on July 15. The initial share sale ...

The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, ...

Among investor categories, Non-Institutional Investors (NIIs) have shown the highest interest, bidding 1.55 times their ...

Anthem Biosciences' IPO fully subscribed, investors optimistic about growth prospects amid global pharma shift from China to ...

Anthem Biosciences IPO on Day 2 with moderate success, price band ₹540-570, 35% reserved for retail investors.

The mainline issue will close for public subscription on Wednesday, July 16. The basis of allotment of shares is likely to be ...

With a unique business model rooted in innovation-led drug development services, the company is betting big on global ...

The grey market premium for Anthem Biosciences IPO rose from Rs 116 on Monday to Rs 123, as of 10:32 a.m., according to ...

Anthem Biosciences has launched its IPO on July 14, closing on July 16. The ₹3,395 crore offer is entirely for sale by ...

Anthem Biosciences, ₹3,395 crore IPO was fully subscribed by Day 2, with strong interest from non-institutional investors, ...